Adavosertib, also known as AZD1775, is an experimental anticancer drug. It is an inhibitor of the Wee1 kinase, an enzyme that plays a critical role in the regulation of the cell cycle. By inhibiting Wee1 kinase, adavosertib disrupts the cell cycle, leading to cell death, particularly in cancer cells with DNA damage or defective DNA repair mechanisms.
